<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/">

<channel>
	<title>P. V. Ramprasad Reddy | Business Upturn</title>
	<atom:link href="https://www.businessupturn.com/news/topic/p-v-ramprasad-reddy/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.businessupturn.com</link>
	<description>India&#039;s leading business and financial news portal — markets, economy, stocks and corporate news.</description>
	<lastBuildDate>Sat, 16 May 2026 16:12:40 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://www.businessupturn.com/wp-content/uploads/2023/07/favicon-150x150.jpg</url>
	<title>P. V. Ramprasad Reddy | Business Upturn</title>
	<link>https://www.businessupturn.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Aurobindo Pharma promoters face Rs 6.53 crore settlement order</title>
		<link>https://www.businessupturn.com/business/aurobindo-pharma-promoters-face-rs-6-53-crore-settlement-order/</link>
		
		<dc:creator><![CDATA[Yash Agarwal]]></dc:creator>
		<pubDate>Sat, 16 May 2026 16:12:40 +0000</pubDate>
				<category><![CDATA[Business]]></category>
		<category><![CDATA[Aurobindo Pharma]]></category>
		<category><![CDATA[P. V. Ramprasad Reddy]]></category>
		<category><![CDATA[SEBI]]></category>
		<category><![CDATA[Telangana High Court]]></category>
		<guid isPermaLink="false">https://www.businessupturn.com/business/aurobindo-pharma-promoters-face-rs-6-53-crore-settlement-order/</guid>

					<description><![CDATA[The High Court of Telangana dismissed a writ petition by Aurobindo Pharma promoters regarding a SEBI settlement order, involving a ₹6.53 crore deposit directive.]]></description>
										<content:encoded><![CDATA[&lt;p&gt;The Hon’ble High Court of Telangana, Hyderabad, has dismissed a writ petition filed by the promoters of &lt;a href=&quot;https://www.businessupturn.com/news/topic/aurobindo-pharma/&quot; rel=&quot;tag&quot;&gt;Aurobindo Pharma&lt;/a&gt; regarding a settlement order issued by the Securities and Exchange Board of India (&lt;a href=&quot;https://www.businessupturn.com/news/topic/sebi/&quot; rel=&quot;tag&quot;&gt;SEBI&lt;/a&gt;). The court’s decision, dated May 6, 2026, pertains to a case involving alleged violations of insider trading regulations.&lt;/p&gt;
&lt;p&gt;The petitioners, including Mr. &lt;a href=&quot;https://www.businessupturn.com/news/topic/p-v-ramprasad-reddy/&quot; rel=&quot;tag&quot;&gt;P. V. Ramprasad Reddy&lt;/a&gt;, Ms. P. Suneela Rani, Mr. Kambam Prasad Reddy, and Trident Chemphar Limited, had initially filed a settlement application with SEBI under the Securities and Exchange Board of India (Settlement) Regulations, 2018. SEBI’s settlement order, issued on May 6, 2020, required the petitioners to address alleged violations of Regulations 3 and 4, read with Regulation 12 (2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992.&lt;/p&gt;
&lt;p&gt;On October 23, 2020, SEBI directed the petitioners to deposit ₹6.53 crores, representing profits made from trading in Aurobindo Pharma shares, along with 12% annual interest from the date of violation to the date of filing revised settlement terms, into the Investor Protection and Education Fund within 15 days. This directive, referred to as the ‘Impugned Communication,’ prompted the petitioners to seek legal recourse through a writ petition.&lt;/p&gt;
&lt;p&gt;The High Court’s dismissal of the writ petition means the petitioners must comply with SEBI’s directive. The petitioners are now consulting with their legal advisors to determine their next steps in response to the court’s order.&lt;/p&gt;
&lt;p&gt;Aurobindo Pharma has clarified that the court’s decision does not impact the company’s financials, operations, or other activities, as the order is directed against the petitioners and not the company itself.&lt;/p&gt;
&lt;p&gt;Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).&lt;/p&gt;
]]></content:encoded>
					
		
		
		<media:content url="https://www.businessupturn.com/wp-content/uploads/2020/11/Aurobindo-Pharma-1.jpg" medium="image" width="1200" height="675"><media:title type="html"><![CDATA[AUROPHARMA - Aurobindo Pharma Limited]]></media:title></media:content>
<media:thumbnail url="https://www.businessupturn.com/wp-content/uploads/2020/11/Aurobindo-Pharma-1.jpg" width="1200" height="675" />
	</item>
	</channel>
</rss>
